Dr. Chris Chen is currently Chief Executive Officer at WuXi Biologics, leading a 1500-member team providing end-to-end biologics services to global partners. At WuXi he has built a world-class open-access integrated mab discovery, development and manufacturing platform serving full spectrum of companies ranging from virtual companies to
12 large pharma. Under his leadership, WuXi has assembled one of the
largest biologics development teams with over 700 scientists enabling 40 global INDs in two years. WuXi is also currently building the largest disposable-bioreactor based state-of-the-art commercial manufacturing facility totaling 30,000L bioreactor capacity in the world. He obtained his dual bachelor degrees of chemical engineering and automation at Tsinghua University, Beijing China and his Ph.D. in chemical engineering at the University of Delaware, US. He then gained valuable experience in process development, manufacturing, technology transfer, process validation, quality, and regulatory in the US, where his previous assignments include director and manager positions of bioprocess development, technical service, and pilot plant operations at Lilly and Merck. Dr. Chen later joined Shanghai Celgen Biopharmaceuticals as Chief Operating Officer, successfully developed a high-titer high-quality commercial process for biosimilar Enbrel, and obtained regulatory approval for the program in China in
2011. He chaired multiple conferences in biochemical engineering and mab development in US and
China and is frequently invited to speak at multiple conferences. He is also adjunct professor at Shanghai
Jiaotong University. Dr Chen is co-author and co-inventor of 40+ publications and patents.